{"transactions":[{"id":2235912,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:05:22.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":19000,"derivative":{"exercise_price":13.56,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0000899243-22-021888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322021888/doc4.xml","form_type":"4"}},{"id":2438923,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":8400,"derivative":{"exercise_price":19,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438922,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":1621544,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1621544},"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438921,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":974107,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":974107},"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438920,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":6410964,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6410964},"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438919,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":1409035,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1409035},"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438918,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"purchase","acquired":true,"shares":6578,"price":19,"value":124982.0,"ownership":{"direct":true},"balance_after":6578,"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438917,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":1621544,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":10415650,"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438916,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":974107,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":8794106,"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438915,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":6410964,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":7819999,"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2438914,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:35:56.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":1409035,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1  and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares."}],"balance_after":1409035,"source":{"system":"sec-edgar","filing":"0000899243-22-001525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001525/doc4.xml","form_type":"4"}},{"id":2997178,"issuer":{"id":5580,"kind":"organization","name":"Atea Pharmaceuticals, Inc."},"owners":[{"id":126306,"kind":"person","name":"Cheng Isaac","position":1,"cik":"0001829696","reported_name":"Cheng Isaac","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-30T21:39:18.000Z","date":"2020-10-29","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 36 equal monthly installments following October 29, 2020."}],"balance_after":80000,"derivative":{"exercise_price":24,"expiration_date":"2030-10-28","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000899243-20-029951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1593899/000089924320029951/doc4.xml","form_type":"4"}}]}